NCT00685815View on ClinicalTrials.gov

Intravenous Iron Metabolism in Restless Legs Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2012

Conditions
Restless Legs
Interventions
DRUG

Ferric Carboxymaltose (FCM)

500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

DRUG

Placebo

250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

Trial Locations (1)

21224

The Johns Hopkins Bayview Medical Center, Baltimore

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

American Regent, Inc.

INDUSTRY

NCT00685815 - Intravenous Iron Metabolism in Restless Legs Syndrome | Biotech Hunter | Biotech Hunter